Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Any believers in UPS who buy now can enjoy a generous dividend payment every quarter while waiting for a turnaround. Given ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Let's discuss how the drugs in these two non-oncology segments are expected to have performed in the third quarter. In ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

According to Pfizer Inc. (NYSE:PFE), the BREAKWATER study shows statistically significant and clinically meaningful results, ...

Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...